Key facts
- It has raised $1.0M.
- Notable investors include Bpifrance, Eurobiomed, Incubator Provence Côte d'Azur, L'Agence Nationale de la Recherche, Medicen.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Algenscribe
- ·The full record, as it builds
Funding rounds
No funding rounds for Algenscribe are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Algenscribe
Developer of a gene editing platform designed to improve human health. The company applies a unique toolbox for precise gene editing for Gene Replacement and Base Editing, enabling users to increase the efficiency of homologous recombination and addressing some limitations related to nuclease-based gene editing.
- Sector
- Healthcare
- HQ
- Nice, France
- Founded
- 2022
- Employees
- 2
- Website
- algenscribe.fr/
- Ownership
- Privately Held (backing)
Algenscribe doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Algenscribe shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Algenscribe in its N-PORT filings yet. We sweep new filings monthly.